About iBio
iBio is a publicly listed company based in Wilmington (United States) founded in 2008. Biologics products are developed using transient gene expression in plants. The company has 20 employees. iBio offers products and services including Discovery Platform and Therapeutic Pipeline. Its focus areas include Life Sciences, Immunology, Drugs and Fibrosis. Its legal entity is iBio, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2008 and headquartered in Wilmington, United States, iBio operates in the biotechnology sector. Biologics, including monoclonal antibodies, therapeutic proteins, and vaccines, are produced through the iBioLaunch platform, which employs transient gene expression in unmodified green plants. The iBioModulator platform supports development of proprietary and biosimilar products. Operations include optional robotic, multi-product manufacturing facilities for these applications.
- Headquarters Wilmington, United States
- Employees 20
- Stage Public
- SectorsHealthcare
- Website ibioinc.com
- Social LinkedIn
- Legal Name Ibio, Inc.
- Annual Revenue$100 K (USD)-75as on Jun 30, 2026
- Net Profit-$33.04 M (USD)-79.81as on Jun 30, 2026
- EBITDA-$29.11 M (USD)-66.56as on Jun 30, 2026
- Latest Funding Round$6.2M (USD), Post-IPO
Apr 2025
- Investors
- Employee Count20
Products & Services of iBio
iBio offers a comprehensive portfolio of products and services, including Discovery Platform and Therapeutic Pipeline.
Platform for identifying and optimizing antibodies for therapeutics
Pipeline of antibodies targeting obesity and metabolic diseases
Funding Insights of iBio
- Total Rounds 5
- Last Round Post-IPO — $6.2M
- First Round $3M
(Sep 2009)
- Investors Count 1
All 5 funding rounds of iBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $6.2M | Post-IPO | – | – | – |
| Mar 2020 | Post-IPO | – | – | ||
| Feb 2016 | $2.2M | Post-IPO | – | – | – |
| Nov 2010 | $7.07M | Post-IPO | – | – | – |
| Sep 2009 | $3M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in iBio
iBio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Lincoln Park Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States |
Investor details for iBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of iBio
27 people are tracked at iBio (11 in leadership, 10 in board & advisors, 6 in team); the tracked headcount is 20.
| Name | Role | Group |
|---|---|---|
Ramona Hofmann | Regional Director Of Sales And Marketing | Leadership |
Estee Silk | VP And Corporate Controller | Leadership |
Lufei Hu | Director, In Vivo Pharmacology | Leadership |
Kristi Sarno | Senior Vice President Business Development | Leadership |
Martin Brenner | CEO & CSO | Leadership |
Brian R. Berquist | VP, Downstream Process Development and Manufacturing | Leadership |
Alexander Taguchi | Director of Machine Learning | Leadership |
Felipe Duran | Interim Chief Financial Officer | Leadership |
Cory Schwartz | Director, Research And Early Development | Leadership |
Marc Banjak | Chief Legal Officer | Leadership |
Michael Shassere | Director Of Information Technology | Leadership |
Robert B. Kay | Co-Chairman | Board & advisors |
Seymour Flug | Director | Board & advisors |
General James T. Hill | Director | Board & advisors |
John D. McKey | Director | Board & advisors |
Philip K. Russell | Director | Board & advisors |
Glenn Chang | Director | Board & advisors |
Chip Clark | Chairman | Board & advisors |
Gary Sender | Director | Board & advisors |
Eef Schimmelpennink | Director | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for iBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of iBio
iBio is a publicly listed company on the NASDAQ with ticker symbol IBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Aug 2008
- Listed onNYSEAMERICAN: IBIO
- Listed entityiBio, Inc.
- Exchange sectorHealth technology
- ISINUS4510337086
- Share price$0.78 (-13.44% on the day) · 2026-10-13
- Market capitalisation$47.6M
- EPS (diluted, trailing year)$-0.45
- Volume (last session)1,350,965
Financials of iBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | $100,000 | -$33.0M | -$29.1M |
| 2025 | $400,000 | -$18.4M | -$17.5M |
| 2024 | $225,000 | -$24.9M | -$15.4M |
| 2023 | -$65.0M | -$27.7M | |
| 2022 | $1.9M | -$50.3M | -$25.9M |
Detailed financial statements for iBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of iBio
4 dated milestones of iBio across 17 years, from founding to its latest funding, stage changes and deals.
- Founded iBio is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.0M.
- Funding Latest funding round, Post-IPO, of $6.2M.
Competitors of iBio
iBio has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of iBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of iBio
The website of iBio (ibioinc.com) receives about 8.5K visits a month.
- Monthly visits8.5K
▼ 6.2% vs previous month
Websites whose visitors overlap most with iBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pioneeringtech.com | 100% | 2.8K | #6,498,848 | View details | |
| dufutechnology.com | 100% | 1.1K | #10,630,615 | View details | |
| evogene.com | 62% | 6.1K | #3,164,557 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as iBio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ibio
Complete news archive for iBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iBio
iBio was founded in 2008 and raised its 1st funding round 1 year after it was founded.
iBio is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
iBio has 20 employees.
Annual revenue of iBio is $100K as on Jun 30, 2026.
Founded in 2008 and headquartered in Wilmington, United States, iBio operates in the biotechnology sector. Biologics, including monoclonal antibodies, therapeutic proteins, and vaccines, are produced through the iBioLaunch platform, which employs transient gene expression in unmodified green plants. The iBioModulator platform supports development of proprietary and biosimilar products. Operations include optional robotic, multi-product manufacturing facilities for these applications.
iBio's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
iBio offers Discovery Platform and Therapeutic Pipeline.
Yes, iBio is publicly traded on NASDAQ under the ticker symbol IBIO.
iBio has 1 investor. Key investors include Lincoln Park Capital.
iBio operates through Ibio, Inc..